Who are Xtoro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Besivance, Factive, Factive, Floxin, Noroxin, Gatifloxacin Ophthalmic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/finafloxacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Xtoro — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xtoro (FINAFLOXACIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Quinolone Antimicrobial. Area: Infectious Disease.

marketed Quinolone Antimicrobial Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Xtoro (FINAFLOXACIN) — Fonseca Biosciences.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xtoro TARGET	FINAFLOXACIN	Fonseca Biosciences	marketed	Quinolone Antimicrobial		2014-01-01
Besivance	BESIFLOXACIN	Bausch Health	marketed	Quinolone Antimicrobial [EPC]		2009-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	marketed	Quinolone Antimicrobial		2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	marketed	Quinolone Antimicrobial		2003-01-01
Floxin	OFLOXACIN		marketed	Quinolone Antimicrobial [EPC]	Histamine H3 receptor	1990-01-01
Noroxin	NORFLOXACIN		marketed	Quinolone Antimicrobial	Gamma-aminobutyric acid receptor subunit alpha-1	1986-01-01
Gatifloxacin Ophthalmic	Gatifloxacin Ophthalmic	Carolina Eyecare Physicians, LLC	marketed	Quinolone Antimicrobial [EPC]

Recent regulatory actions (last 90 days)

2026-04-08 — Floxin · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Quinolone Antimicrobial class)

Lg Chem Ltd · 2 drugs in this class
· 1 drug in this class
Fonseca Biosciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xtoro — Competitive Intelligence Brief. https://druglandscape.com/ci/finafloxacin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing